CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third quarter 2024 financial results after market close on November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. The company is a specialty pharmaceutical firm with a portfolio of six FDA-approved brands targeting hospital acute care, gastroenterology, and oncology markets. Their products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Additionally, Cumberland has Phase II clinical programs evaluating ifetroban for various conditions including Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) pubblicherà i propri risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il 7 novembre 2024, seguito da una conferenza telefonica alle 16:30 ora orientale. L'azienda è una società farmaceutica specializzata con un portafoglio di sei marchi approvati dalla FDA che mirano ai mercati dell'assistenza acuta in ospedale, della gastroenterologia e dell'oncologia. I loro prodotti includono Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol e Vibativ. Inoltre, Cumberland ha programmi clinici di Fase II che valutano ifetroban per varie condizioni tra cui la sclerodermia sistemica, la cardiomiopatia associata alla distrofia muscolare di Duchenne e la fibrosi polmonare idiopatica.
Cumberland Pharmaceuticals (Nasdaq: CPIX) publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el 7 de noviembre de 2024, seguido de una conferencia telefónica a las 4:30 p.m. hora del este. La empresa es una firma farmacéutica especializada con un portafolio de seis marcas aprobadas por la FDA que se dirigen a los mercados de cuidado agudo en hospitales, gastroenterología y oncología. Sus productos incluyen Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol y Vibativ. Además, Cumberland tiene programas clínicos de Fase II que evalúan ifetroban para diversas condiciones, incluyendo esclerosis sistémica, miocardiopatía asociada a distrofia muscular de Duchenne y fibrosis pulmonar idiopática.
컴벌랜드 제약(Cumberland Pharmaceuticals) (Nasdaq: CPIX)은 2024년 11월 7일 시장 종료 후 2024년 3분기 재무 결과를 발표하며, 이후 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 진행합니다. 이 회사는 병원 급성 치료, 위장병학 및 종양학 시장을 목표로 하는 6개의 FDA 승인 브랜드를 보유한 전문 제약회사입니다. 이들의 제품에는 Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol 및 Vibativ가 포함됩니다. 또한, 컴벌랜드는 전신 경화증, 뒤센 근육 디스트로피 관련 심근병증 및 특발성 폐 섬유증을 포함한 다양한 상태에 대한 ifetroban의 효과를 평가하는 2상 임상 프로그램을 진행하고 있습니다.
Cumberland Pharmaceuticals (Nasdaq: CPIX) publiera ses résultats financiers du troisième trimestre 2024 après la clôture des marchés le 7 novembre 2024, suivis d'une conférence téléphonique à 16h30 heure de l'Est. L'entreprise est une société pharmaceutique spécialisée avec un portefeuille de six marques approuvées par la FDA ciblant les marchés des soins aigus en milieu hospitalier, de la gastro-entérologie et de l'oncologie. Leurs produits comprennent Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol et Vibativ. De plus, Cumberland a des programmes cliniques de phase II évaluant l'ifetroban pour diverses conditions, y compris la sclérodermie systémique, la cardiomyopathie associée à la dystrophie musculaire de Duchenne et la fibrose pulmonaire idiopathique.
Cumberland Pharmaceuticals (Nasdaq: CPIX) wird seine Finanzresultate für das dritte Quartal 2024 nach Börsenschluss am 7. November 2024 veröffentlichen, gefolgt von einer Telefonkonferenz um 16:30 Uhr Eastern Time. Das Unternehmen ist ein spezialisiertes Pharmaunternehmen mit einem Portfolio von sechs von der FDA zugelassenen Marken, die sich auf die Bereiche akute Krankenhausversorgung, Gastroenterologie und Onkologie konzentrieren. Zu ihren Produkten gehören Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol und Vibativ. Darüber hinaus hat Cumberland klinische Programme der Phase II zur Bewertung von ifetroban bei verschiedenen Erkrankungen, einschließlich systemischer Sklerose, kardiomyopathischer Erkrankung, die mit der Duchenne-Muskeldystrophie verbunden ist, und idiopathischer Lungenfibrose, entwickelt.
- None.
- None.
A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2024-financial-results-302293344.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release Q3 2024 earnings?
What time is Cumberland Pharmaceuticals (CPIX) Q3 2024 earnings call?
How many FDA-approved products does Cumberland Pharmaceuticals (CPIX) have?
What clinical trials is Cumberland Pharmaceuticals (CPIX) currently conducting?
